Name: CD141 (BDCA-3) MicroBead Kit, human
Availability: InStock

Product overview

The CD141 (BDCA-3) MicroBead Kit has been developed for the isolation of CD141 (BDCA-3)

⁺⁺

cells (namely type-2 MDCs or MDC2) from PBMCs. CD141 (BDCA-3)

is expressed at high levels only on a minor subpopulation of myeloid dendritic cells (MDCs) in human blood (about 0.04 % of all PBMCs).

Background information

CD141 (BDCA-3)

⁺⁺

MDCs are CD11c

^dim

, CD123

^–

, CD1c (BDCA-1)

^–

, CD4

⁺

, and do not express lineage markers such as CD3, CD14, CD16, CD19, CD20, and CD56. They express myeloid markers such as CD13 and CD33 and are monocytoid in appearance (fig. 2). In contrast to CD1c (BDCA-1)

⁺

MDCs, CD141 (BDCA-3)

⁺⁺

MDCs do not express CD2 and Fc receptors such as CD32, CD64, and FceRI. Furthermore, CD141 (BDCA-3)

⁺⁺

MDCs differ from CD1c (BDCA-1)

⁺

MDCs in terms of Toll-like receptor expression, cytokine production, and T helper cell polarization.

In order to discriminate the CD141 (BDCA-3)

⁺⁺

from CD1c (BDCA-1)

⁺

MDCs, they have been designated type-2 MDCs (MDC2s).

The CD141 (BDCA-3) antigen is also expressed at a much lower level on CD1c (BDCA-1)

⁺

MDCs, plasmacytoid dendritic cells, monocytes, and granulocytes in blood.

Downstream applications

CD141 (BDCA-3)

⁺⁺

MDCs were separated for their further phenotypic and functional characterization

^1,3

, for gene clustering

⁶

, or for expression analyses of newly defined antigen EMR2 on different dendritic cell subsets

⁴

. The CD141 (BDCA-3) MicroBead Kit was also used for isolation of human CD141 (BDCA-3)

⁺⁺

MDCs from mice engrafted with CD34

⁺

hematopoietic progenitors.

⁵

Columns

MS, LS, or autoMACS

^®

Columns.

Product data and images

Figure 1

Isolation of CD141 (BDCA-3)

⁺⁺

myeloid dendritic cells from PBMCs using the CD141 (BDCA-3) MicroBead Kit, a MiniMACS™ Separator, and MS Columns. Cells were stained with CD141 (BDCA-3)-PE and CD14-FITC. Only very few CD1c (BDCA-1)

⁺

myeloid dendritic cells, CD303 (BDCA-2)

⁺

plasmacytoid dendritic cells, and CD14

⁺

monocytes are coenriched, although they express CD141 (BDCA-3) at low levels.

PBMCs before separation	Enriched CD141 (BDCA-3) ⁺⁺ myeloid dendritic cells

Figure 2
View details

Figure 2

CD141 (BDCA-3)
⁺⁺
type-2 myeloid dendritic cells, May-Grünwald/Giemsa stained.

CD141 (BDCA-3)
⁺⁺
type-2 myeloid dendritic cells, May-Grünwald/Giemsa stained.

Scientific resources

Selected references
1. Dzionek, A. et al. (2000) BDCA-2, BDCA-3, BDCA-4: Three markers for distinct subsets of dendritic cells in human peripheral blood. J. Immunol. 165: 6037-6046
2. Grabbe, S. et al. (2000) Dendritic cells: multi-lineal and multi-functional. Immunol. Today 21: 431-433
3. Lebre, C. M. et al. (2003)
  BDCA-3
  ^hi
  dendritic cells: a novel subset with distinct phenotypical characteristics. Doctoral dissertation.
  University of Amsterdam, Netherlands
4. Kwakkenbos, M. J. et al. (2002) The human EGF-TM7 family member EMR2 is a heterodimeric receptor expressed on myeloid cells. J. Leukoc. Biol. 71(5): 854-862
5. Palucka, A. K. et al. (2003)
  Human dendritic cell subsets in NOD/SCID mice engrafted with CD34
  ⁺
  hematopoietic progenitors.
  Blood 102: 3302-3310
6. Lindstedt, M. et al. (2005)
  Gene family clustering identifies functionally associated subsets of human
  in vivo
  blood and tonsillar dendritic cells.
  J. Immunol. 175: 4839-4846
Scientific posters

Fully automated clinical-grade isolation of CD141 (BDCA-3)
⁺
cross-presenting dendritic cells (ICC 2017)

Product options: 1

130-090-512